ArticleBMC infectious diseases2026
Clinical characteristics and outcomes of invasive fungal infections in critically ill patients with liver cirrhosis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsInvasive fungal infections (IFIs) are increasingly recognized as a severe and often underdiagnosed complication in critically ill patients with liver cirrhosis. Cirrhosis-associated immune dysfunction, and advanced disease stage contribute to an elevated risk, particularly in the intensive care unit (ICU). Despite their high mortality, data on the epidemiology and timing of IFIs in ICU-treated cirrhotic patients remain limited. We aimed to determine the prevalence, timing, and impact of IFIs on 30- and 90-day survival in this high-risk population.
methodsThis retrospective single-center cohort study included 488 patients with liver cirrhosis who were admitted to ICU between January 2014 and December 2019. Patients were evaluated for the presence of IFIs during their hospital stay and stratified into Non-IFI (n = 458) and IFI (n = 30) groups. Comparative analyses were performed with a specific focus on invasive candidiasis and invasive pulmonary aspergillosis.
resultsIFI prevalence was 6.1%. Invasive candidiasis and invasive pulmonary aspergillosis were diagnosed in 46.7% and 53.3% of IFI cases, with a median onset of 14.5 (6.50-24.00) and 17.5 (7.75-36.00) days, respectively. IFI patients had significantly more advanced liver disease reflected by higher MELD (p < 0.001) score and more severe ACLF (p = 0.009) and required significantly more invasive procedures such as dialysis (p < 0.001) parenteral nutrition (p < 0.001), and mechanical ventilation (p = 0.002). In addition, bacterial infections at admission were more common in IFI patients. The occurrence of IFI was associated with significantly reduced 30- and 90-day survival, particularly in patients with ACLF.
conclusionThese findings highlight the need for IFI surveillance in critically ill cirrhosis patients, particularly in those with ACLF and bacterial infections at admission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.